Virus-Like Particles and Nanoparticles for Vaccine Development against HCMV.
Animals
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ immunology
Antigen Presentation
Clinical Trials as Topic
Cytomegalovirus
Cytomegalovirus Infections
/ prevention & control
Humans
Immunity, Humoral
Immunocompromised Host
Mice
Nanoparticles
/ administration & dosage
Vaccines, Virus-Like Particle
/ immunology
Viral Envelope Proteins
/ immunology
HCMV
VLP
cytomegalovirus
immune response
nanoparticle
vaccine
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
28 12 2019
28 12 2019
Historique:
received:
22
11
2019
revised:
21
12
2019
accepted:
25
12
2019
entrez:
8
1
2020
pubmed:
8
1
2020
medline:
29
9
2020
Statut:
epublish
Résumé
Human cytomegalovirus (HCMV) infects more than 70% of the human population worldwide. HCMV is responsible for high morbidity and mortality in immunocompromised patients and remains the leading viral cause of congenital birth defects. Despite considerable efforts in vaccine and therapeutic development, HCMV infection still represents an unmet clinical need and a life-threatening disease in immunocompromised individuals and newborns. Immune repertoire interrogation of HCMV seropositive patients allowed the identification of several potential antigens for vaccine design. However, recent HCMV vaccine clinical trials did not lead to a satisfactory outcome in term of efficacy. Therefore, combining antigens with orthogonal technologies to further increase the induction of neutralizing antibodies could improve the likelihood of a vaccine to reach protective efficacy in humans. Indeed, presentation of multiple copies of an antigen in a repetitive array is known to drive a more robust humoral immune response than its soluble counterpart. Virus-like particles (VLPs) and nanoparticles (NPs) are powerful platforms for multivalent antigen presentation. Several self-assembling proteins have been successfully used as scaffolds to present complex glycoprotein antigens on their surface. In this review, we describe some key aspects of the immune response to HCMV and discuss the scaffolds that were successfully used to increase vaccine efficacy against viruses with unmet medical need.
Identifiants
pubmed: 31905677
pii: v12010035
doi: 10.3390/v12010035
pmc: PMC7019358
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Vaccines, Virus-Like Particle
0
Viral Envelope Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Références
J Virol. 2012 Jul;86(13):7444-7
pubmed: 22532696
Front Microbiol. 2019 May 15;10:1005
pubmed: 31156572
J Virol. 2013 Apr;87(8):4261-71
pubmed: 23365437
Hum Vaccin Immunother. 2019;15(11):2673-2683
pubmed: 31017831
Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20039-44
pubmed: 21041645
J Med Virol. 1998 May;55(1):64-74
pubmed: 9580888
PLoS Pathog. 2019 Jul 29;15(7):e1007914
pubmed: 31356650
Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):6110-6112
pubmed: 29875141
Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):7043-7052
pubmed: 30894498
Eur J Immunol. 2000 Jun;30(6):1676-82
pubmed: 10898504
Eur J Immunol. 2005 Mar;35(3):816-21
pubmed: 15724244
Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1755-1764
pubmed: 30647114
Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19755-60
pubmed: 22109557
J Virol. 2015 Jan;89(1):361-72
pubmed: 25320309
Curr Top Microbiol Immunol. 2008;325:417-70
pubmed: 18637519
J Med Virol. 2018 Oct;90(10):1620-1628
pubmed: 29797330
Viruses. 2018 Aug 20;10(8):
pubmed: 30127257
J Mol Biol. 2009 Jul 3;390(1):83-98
pubmed: 19427319
Sci Rep. 2016 Jan 19;6:19234
pubmed: 26781591
Ann N Y Acad Sci. 1991 Dec 30;636:184-95
pubmed: 1665321
Hum Immunol. 2004 May;65(5):514-22
pubmed: 15172452
Vaccines (Basel). 2019 Jul 17;7(3):
pubmed: 31319553
Science. 2016 Jul 22;353(6297):389-94
pubmed: 27463675
Eur J Immunol. 2005 Mar;35(3):996-1007
pubmed: 15726667
Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):11879-83
pubmed: 7991550
Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):6273-6278
pubmed: 29686064
Oncoimmunology. 2018 Jan 5;7(3):e1408749
pubmed: 29399414
Annu Rev Biochem. 1987;56:289-315
pubmed: 3304136
PLoS One. 2008 Jun 25;3(6):e2547
pubmed: 18575629
Placenta. 2017 Dec;60 Suppl 1:S73-S79
pubmed: 28456432
Sci Adv. 2018 Nov 21;4(11):eaau6769
pubmed: 30474059
Comput Struct Biotechnol J. 2015 Nov 26;14:58-68
pubmed: 26862374
J Gen Virol. 2015 Feb;96(Pt 2):360-369
pubmed: 25316796
J Nanobiotechnology. 2016 Apr 27;14:30
pubmed: 27117585
J Virol. 2011 Jul;85(14):7465-71
pubmed: 21593144
J Biol Chem. 2016 Jun 3;291(23):12014-28
pubmed: 27129252
Cell. 1994 Jun 17;77(6):943-50
pubmed: 8004680
Cell. 2019 Mar 7;176(6):1420-1431.e17
pubmed: 30849373
J Infect Dis. 2018 May 25;217(12):1907-1917
pubmed: 29528415
Nature. 2014 Jun 5;510(7503):103-8
pubmed: 24870237
Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):E690-7
pubmed: 22366317
J Virol. 2000 Sep;74(17):8140-50
pubmed: 10933725
Proc Natl Acad Sci U S A. 2018 Oct 16;115(42):E9889-E9898
pubmed: 30275317
PLoS Pathog. 2016 Apr 15;12(4):e1005564
pubmed: 27082872
J Infect Dis. 1995 May;171(5):1115-21
pubmed: 7751685
Vaccine. 2019 Nov 28;37(50):7437-7442
pubmed: 29622379
N Engl J Med. 2014 Jun 26;370(26):2544-5
pubmed: 24963582
Immunity. 2018 Aug 21;49(2):301-311.e5
pubmed: 30076101
Nat Microbiol. 2016 Jun 06;1(8):16082
pubmed: 27573107
PLoS One. 2013;8(3):e59863
pubmed: 23555812
PLoS Pathog. 2011 Aug;7(8):e1002172
pubmed: 21852946
Immunity. 2019 May 21;50(5):1305-1316.e6
pubmed: 30979688
J Virol. 2010 Mar;84(5):2585-96
pubmed: 20032184
J Virol. 2010 Jan;84(2):1005-13
pubmed: 19889756
J Infect Dis. 1992 Sep;166(3):473-9
pubmed: 1323614
Nature. 2016 Dec 8;540(7632):292-295
pubmed: 27919066
mBio. 2018 May 8;9(3):
pubmed: 29739904
PLoS Pathog. 2013;9(7):e1003463
pubmed: 23853586
Nat Commun. 2019 Sep 19;10(1):4272
pubmed: 31537780
J Exp Med. 2005 Sep 5;202(5):673-85
pubmed: 16147978
Biochemistry. 2017 Jul 18;56(28):3596-3606
pubmed: 28682599
PLoS Pathog. 2014 Oct 09;10(10):e1004377
pubmed: 25299639
Cell. 2018 Aug 23;174(5):1158-1171.e19
pubmed: 30057110
Nat Immunol. 2019 Mar;20(3):362-372
pubmed: 30742080
Clin Infect Dis. 2017 Oct 30;65(10):1659-1665
pubmed: 29020188
Clin Vaccine Immunol. 2014 Feb;21(2):174-80
pubmed: 24334684
Nat Commun. 2019 Jun 20;10(1):2699
pubmed: 31221976
Br Med Bull. 2019 Sep 19;131(1):5-17
pubmed: 31580403
Hum Vaccin. 2005 Jan-Feb;1(1):16-23
pubmed: 17038834
FEBS Lett. 1998 Jul 10;431(1):7-11
pubmed: 9684855
J Virol. 2004 Oct;78(20):10960-6
pubmed: 15452216
Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):17965-70
pubmed: 25453106
J Gen Virol. 2006 Apr;87(Pt 4):777-87
pubmed: 16528025
Nature. 2016 Dec 1;540(7631):150
pubmed: 27760110
J Biol Chem. 2008 Nov 28;283(48):33508-15
pubmed: 18826949
Immunity. 2018 Jan 16;48(1):133-146.e6
pubmed: 29287996
J Virol. 2015 Sep;89(17):8999-9009
pubmed: 26085146
Viruses. 2018 Aug 20;10(8):
pubmed: 30127279
ACS Infect Dis. 2018 May 11;4(5):788-796
pubmed: 29451984
Science. 2012 Nov 23;338(6110):1088-93
pubmed: 23180859
Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18153-8
pubmed: 16319222
J Immunol. 2004 Aug 1;173(3):1834-41
pubmed: 15265915
Viruses. 2018 Dec 11;10(12):
pubmed: 30544948
J Virol. 2005 Sep;79(17):11022-34
pubmed: 16103153
mBio. 2013 Jun 04;4(3):e00332-13
pubmed: 23736286
Cell. 2015 Aug 27;162(5):1090-100
pubmed: 26279189
Nat Rev Immunol. 2002 Nov;2(11):831-44
pubmed: 12415307
Front Immunol. 2016 Sep 15;7:352
pubmed: 27695453
Immunotherapy. 2016 Sep;8(9):1135-49
pubmed: 27485084
Structure. 1996 May 15;4(5):543-54
pubmed: 8736553
J Infect Dis. 2016 Dec 15;214(12):1916-1923
pubmed: 27923951
Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15821-6
pubmed: 16247012
J Infect Dis. 2019 Jun 19;220(2):228-232
pubmed: 30815685
Front Microbiol. 2019 May 28;10:1186
pubmed: 31191499
J Gen Virol. 1991 Sep;72 ( Pt 9):2059-64
pubmed: 1654370
Science. 2019 May 17;364(6441):658-664
pubmed: 31097662
Virology. 1996 Aug 1;222(1):293-6
pubmed: 8806513
Nat Rev Immunol. 2010 Nov;10(11):787-96
pubmed: 20948547
PLoS Pathog. 2015 Oct 20;11(10):e1005230
pubmed: 26485028
J Clin Invest. 2010 Nov;120(11):4077-90
pubmed: 20921622
Ital J Pediatr. 2017 Apr 17;43(1):38
pubmed: 28416012
J Clin Virol. 2008 Mar;41(3):206-12
pubmed: 18069056
Eur J Immunol. 2008 May;38(5):1404-13
pubmed: 18389478
Curr Opin Virol. 2018 Aug;31:43-51
pubmed: 29866439
NPJ Vaccines. 2018 Sep 20;3:38
pubmed: 30275984
Nat Commun. 2016 Feb 24;7:10618
pubmed: 26907590
J Gen Virol. 1996 Dec;77 ( Pt 12):3099-102
pubmed: 9000102
Blood. 2007 Aug 1;110(3):937-45
pubmed: 17440050
Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):6267-6272
pubmed: 29712861
Retrovirology. 2015 Sep 26;12:82
pubmed: 26410741
Viruses. 2014 Mar 19;6(3):1346-64
pubmed: 24651029
PLoS Pathog. 2013;9(10):e1003635
pubmed: 24130479
J Virol. 2001 Jul;75(13):5949-57
pubmed: 11390596
J Gen Virol. 2010 Mar;91(Pt 3):599-604
pubmed: 19906945
Proc Natl Acad Sci U S A. 1988 Oct;85(20):7457-61
pubmed: 2845407
Rev Med Virol. 2007 Jul-Aug;17(4):253-76
pubmed: 17579921
PLoS Pathog. 2017 Apr 12;13(4):e1006281
pubmed: 28403202
Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1767-72
pubmed: 25624487
EBioMedicine. 2019 Dec;50:45-54
pubmed: 31735553
Curr Opin Pediatr. 2016 Feb;28(1):81-5
pubmed: 26709686
J Virol. 1998 Oct;72(10):8191-7
pubmed: 9733861
Nat Commun. 2016 Jun 28;7:12041
pubmed: 27349934